Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives
Elena Niculet,1,2,* Carmen Bobeica,1 Ioana Anca Stefanopol,1,3 Ana Maria Pelin,4,* Alexandru Nechifor,2,5,* Cristian Onisor,1,* Alin Laurentiu Tatu2,4,5 1Department of Morphological and Functional Sciences, Faculty of Medicine and Pharmacy, “Dunărea de Jos”...
Main Authors: | Niculet E, Bobeica C, Stefanopol IA, Pelin AM, Nechifor A, Onisor C, Tatu AL |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-04-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/once-daily-abrocitinib-for-the-treatment-of-moderate-to-severe-atopic--peer-reviewed-fulltext-article-TCRM |
Similar Items
-
Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial
by: Carsten Flohr, et al.
Published: (2023-12-01) -
Research progress on abrocitinib in the treatment of moderate and severe atopic dermatitis
by: Xu ZHU, et al.
Published: (2023-08-01) -
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
by: Helena Iznardo, et al.
Published: (2023-01-01) -
Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
by: Ling Li, et al.
Published: (2023-05-01) -
The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data
by: Napolitano M, et al.
Published: (2021-03-01)